Drug Induced Mitochondrial Toxicity: Mechanistic Diversity and Deleterious Consequences for the liver

PharmaTutor (January- 2014)
ISSN: 2347 - 7881

Received On: 28/12/2013; Accepted On: 04/01/2014; Published On: 15/01/2014

About Authors: Keyur S. Patel*, Mital Mehta
Department of Pharmacology,
Anand Pharmacy College, Anand,
Gujarat, India.

ABSTRACT: Drug-induced liver injury (DILI) has become a leading cause of severe liver disease and withdrawal of an approved drug from the market. DILI accounts for acute liver failure, liver transplantation or death in the United States today. A recent retrospective study indicates that the risk of DILI is enhanced when the administered daily dosage is higher than 50 mg or when the drug undergoes significant liver metabolism. Hence airs a major clinical and regulatory challenge.
This review sum up direct mitochondrial impairment and Specific drug induced mitochondrial dysfunction, current mechanistic concepts of DILI in a 2-step model that limits its principle mechanisms to this main ways of initial injury. Umpteen Studies that evaluate the risk of hepatotoxicity from Statins in Hyperlipidemic Patients. In this article, It will review the pathogenesis of drug induced mitochondrial liver toxicity and deleterious consequences of Atorvastatin.

How to cite this article: KS Patel, M Mehta, Drug Induced Mitochondrial Toxicity: Mechanistic Diversity and Deleterious Consequences for the liver, PharmaTutor, 2014, 2(1), 33-39

[ABSTRACT WITH CITATION] [VIEW AS HTML]

REFERENCES:
1. Rao AS, Ahmed MF, Ibrahim M. Hepatoprotective activity of Melia azedarach leaf extract against simvastatin induced Hepatotoxicity in rats. Journal of Applied Pharmaceutical Science, 2012, 2(07): 144-8.
2. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol, 2011, 54(4): 773-94.
3. MITCHELL P. Compartmentation and communication in living systems. Ligand conduction: a general catalytic principle in chemical, osmotic and chemiosmotic reaction systems. Eur J Biochem, 1979, 95(1): 1-20.
4. Bernardi P, Krauskopf A, Basso E, Petronilli V, Blalchy?Dyson E, Di Lisa F, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS Journal, 2006, 273(10): 2077-99.
5. Labbe G, Pessayre D, Fromenty B. Drug?induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol, 2008, 22(4): 335-53.
6. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Adverse Drug Reactions: Springer; 2010. p. 311-65.
7. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology,2006, 43(S1): S31-S44.
8. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nature reviews Drug discovery,2010, 9(6): 447-64.
9. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med,2000, 6(5): 513-9.
10. Buron N, Porceddu M, Brabant M, Desgué D, Racoeur C, Lassalle M, et al. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One, 2010, 5(3): e9924.
11. Balakirev MY, Zimmer G. Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition. Chem Biol Interact, 2001, 138(3): 299-311.
12. Belosludtsev KN, Saris N-EL, Belosludtseva NV, Trudovishnikov AS, Lukyanova LD, Mironova GD. Physiological aspects of the mitochondrial cyclosporin A-insensitive palmitate/Ca2+-induced pore: tissue specificity, age profile and dependence on the animal’s adaptation to hypoxia. J Bioenerg Biomembr, 2009, 41(4): 395-401.
13. Eliseev RA, Filippov G, Velos J, VanWinkle B, Goldman A, Rosier RN, et al. Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition. Neurobiol Aging, 2007, 28(10): 1532-42.
14. Mirandola SR, Melo DR, Saito Â, Castilho RF. 3?nitropropionic acid?induced mitochondrial permeability transition: Comparative study of mitochondria from different tissues and brain regions. J Neurosci Res, 2010, 88(3): 630-9.
15. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annual review of pathology, 2010, 5 297.
16. Seifert EL, Estey C, Xuan JY, Harper M-E. Electron transport chain-dependent and-independent mechanisms of mitochondrial H2O2 emission during long-chain fatty acid oxidation. J Biol Chem, 2010, 285(8): 5748-58.
17. Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxidants & redox signaling, 2009, 11(11): 2685-700.
18. Fernandez-Checa JC, Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol, 2005, 204(3): 263-73.
19. Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Molecular interventions, 2010, 10(2): 98.
20. Brookes PS. Mitochondrial H + leak and ROS generation: An odd couple. Free Radic Biol Med, 2005, 38(1): 12-23.
21. Tahara EB, Navarete FD, Kowaltowski AJ. Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med, 2009, 46(9): 1283-97.
22. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology, 2002, 123(4): 1278-90.
23. Sanz A, Caro P, Ayala V, Portero-Otin M, Pamplona R, Barja G. Methionine restriction decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to mitochondrial DNA and proteins. The FASEB journal, 2006, 20(8): 1064-73.
24. Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol, 2004, 199(1): 10-9.
25. Fromenty B, Robin M, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab, 2004, 30(2): 121-38.
26. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther, 1995, 67(1): 101-54.
27. Arnaudo E, Shanske S, DiMauro S, Schon E, Moraes C, Dalakas M. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. The Lancet, 1991, 337(8740): 508-10.
28. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′, 3′-dideoxyinosine (ddI). Ann Intern Med, 1991, 115(4): 283-4.
29. Le Bras P, D'Oiron R, Quertainmont Y, Halfon P, Caquet R. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS, 1994, 8(5): 715-6.
30. Nadanaciva S, Will Y. The role of mitochondrial dysfunction and drug safety. IDrugs: the investigational drugs journal, 2009, 12(11): 706-10.
31. Berson A, Cazanave S, Descatoire V, Tinel M, Grodet A, Wolf C, et al. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. J Pharmacol Exp Ther, 2006, 318(1): 444-54.
32. Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of benzarone and benzbromarone?induced hepatic toxicity. Hepatology, 2005, 41(4): 925-35.
33. Trost LC, Lemasters JJ. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J Pharmacol Exp Ther, 1996, 278(3): 1000-5.
34. Berson A, Descatoire V, Sutton A, Fau D, Maulny B, Vadrot N, et al. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther, 2001, 299(2): 793-800.
35. Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology, 2006, 222(3): 233-9.
36. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol, 2005, 42(1): 110-6.
37. Kowaltowski AJ, Castilho RF, Vercesi AE. Mitochondrial permeability transition and oxidative stress. FEBS Lett, 2001, 495(1): 12-5.
38. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Adverse Drug Reactions: Springer; 2010, p. 369-405.
39. Burcham PC, Harman AW. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem, 1991, 266(8): 5049-54.
40. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci, 2002, 65(1): 135-50.
41. Kaplowitz N, Shinohara M, Liu Z-X, Han D. How to protect against acetaminophen: don't ask for JUNK. Gastroenterology, 2008, 135(4): 1047-51.
42. Sohn JH, Han KL, Kim J-H, Rukayadi Y, Hwang J-K, Protective effects of macelignan on cisplatin-induced hepatotoxicity is associated with JNK activation. Biol Pharm Bull, 2008, 31(2): 273-7.
43. Be?towski J, Wójcicka G, Jamroz-Wi?niewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf, 2009, 4(3): 209-28.
44. ULI?NÁ O, VAN?OVÁ O, WACZULÍKOVÁ I, BOŽEK P, ŠIKUROVÁ L, BADA V, et al. Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin. Physiological research/Academia Scientiarum Bohemoslovaca, 2012, 61(2): 185.
45. Cueto R, Valdivielso P, Lucena MI, García-Arias C, Andrade RJ, González-Santos P. Statins: Hepatic Disease and Hepatotoxicity Risk. Open Gastroenterology Journal, 2008, 2 18-23.
46. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA?reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors, 2003, 18(1?4): 101-11.

Search

Drug Induced Mitochondrial Toxicity: Mechanistic Diversity and Deleterious Consequences for the liver

RECOMMENDED POSTS

Subscribe with us

Jobs by Category